Novel quinazolin-sulfonamid derivatives: synthesis, characterization, biological evaluation, and molecular docking studies

In the design of novel drugs, the formation of hybrid molecules via the combination of several pharmacophores can give rise to compounds with interesting biochemical profiles. A series of novel quinazolin-sulfonamid derivatives (9a-m) were synthesized, characterized and evaluated for their in vitro antidiabetic, anticholinergics, and antiepileptic activity. These synthesized novel quinazolin-sulfonamid derivatives (9a-m) were found to be effective inhibitor molecules for the alpha-glycosidase, human carbonic anhydrase I and II (hCA I and hCA II), butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) enzyme, with Ki values in the range of 100.62 +/- 13.68-327.94 +/- 58.21 nM for alpha-glycosidase, 1.03 +/- 0.11-14.87 +/- 2.63 nM for hCA I, 1.83 +/- 0.24-15.86 +/- 2.57 nM for hCA II, 30.12 +/- 3.81-102.16 +/- 13.87 nM for BChE, and 26.16 +/- 3.63-88.52 +/- 20.11 nM for AChE, respectively. In the last step, molecular docking calculations were made to compare biological activities of molecules against enzymes which are achethylcholinesterase, butyrylcholinesterase and alpha-glycosidase.